Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ESK-001-023

12 evidence topics · 2 sources

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2025-12-10”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using pharmacokinetic parameters and adverse event incidence as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • No pharmacokinetic or adverse event results of the renal impairment study have been posted, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
  • Only participants were masked, allocation was non-randomized, and each participant received a single dose with outcomes assessed over 48 hours.
  • Enrollment was 16 participants, against 48 estimated at registration, at four sites in Florida; the record plans 8 participants each with mild, moderate, and severe renal impairment but does not report how many were enrolled in each group, and participants requiring dialysis were not eligible.